Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance Capecitabine in Metastatic Nasopharyngeal Carcinoma
NCT02460419Phase 3Completed
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2015
- Primary completion
- May 2020
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of capecitabine in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Started Apr 2015; status: completed.
02
Drugs
capecitabine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT02460419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02460419.